Dominari Asimina, Hathaway Iii Donald, Pandav Krunal, Matos Wanessa, Biswas Sharmi, Reddy Gowry, Thevuthasan Sindhu, Khan Muhammad Adnan, Mathew Anoopa, Makkar Sarabjot Singh, Zaidi Madiha, Fahem Michael Maher Mourad, Beas Renato, Castaneda Valeria, Paul Trissa, Halpern John, Baralt Diana
Division of Research and Academic Affairs, Larkin Health System, South Miami, FL 33143, United States.
World J Virol. 2020 Dec 15;9(5):67-78. doi: 10.5501/wjv.v9.i5.67.
Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying, enhancing, and restoring immune function. Thymosin alpha 1 has been utilized in the treatment of immunocompromised states and malignancies, as an enhancer of vaccine response, and as a means of curbing morbidity and mortality in sepsis and numerous infections. Studies have postulated that thymosin alpha 1 could help improve the outcome in severely ill corona virus disease 2019 patients by repairing damage caused by overactivation of lymphocytic immunity and how thymosin alpha 1 could prevent the excessive activation of T cells. In this review, we discuss key literature on the background knowledge and current clinical uses of thymosin alpha 1. Considering the known biochemical properties including antibacterial and antiviral properties, time-honored applications, and the new promising findings regarding the use of thymosin, we believe that thymosin alpha 1 deserves further investigation into its antiviral properties and possible repurposing as a treatment against severe acute respiratory syndrome coronavirus-2.
胸腺肽α1是一种天然存在于胸腺中的肽，长期以来一直因其对免疫功能的调节、增强和恢复作用而受到认可。胸腺肽α1已被用于治疗免疫功能低下状态和恶性肿瘤，作为疫苗反应的增强剂，以及作为降低败血症和多种感染发病率和死亡率的一种手段。研究推测，胸腺肽α1可通过修复淋巴细胞免疫过度激活所造成的损伤，帮助改善重症2019冠状病毒病患者的预后，以及胸腺肽α1如何预防T细胞的过度激活。在这篇综述中，我们讨论了关于胸腺肽α1背景知识和当前临床应用的关键文献。考虑到其已知的生化特性，包括抗菌和抗病毒特性、长期应用以及关于胸腺肽使用的新的有前景的发现，我们认为胸腺肽α1值得进一步研究其抗病毒特性以及作为治疗严重急性呼吸综合征冠状病毒2的可能重新用途。
